Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IL4I1 | Q96RQ9 | 8/20 | 0.77 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 3/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.32 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30948018 | 0.91 | IL4I1 (0.79) | IL4I1RXFP1TP53KCNH2LMNA | |
| SCHEMBL30948343 | 0.91 | IL4I1 (0.79) | IL4I1RXFP1TP53KCNH2LMNA | |
| SCHEMBL27163220 | 0.87 | IL4I1 (1.00) | IL4I1RXFP1TP53KCNH2LMNA | |
| SCHEMBL30046257 | 0.87 | IL4I1 (1.00) | IL4I1RXFP1TP53KCNH2LMNA | |
| SCHEMBL27163156 | 0.87 | IL4I1 (0.80) | IL4I1RXFP1TP53KCNH2LMNA | |
| SCHEMBL30948288 | 0.87 | IL4I1 (0.96) | IL4I1RXFP1TP53KCNH2LMNA | |
| SCHEMBL30948114 | 0.82 | IL4I1 (0.70) | IL4I1RXFP1KCNH2LMNAP2RX7 | |
| SCHEMBL30948012 | 0.79 | IL4I1 (0.84) | IL4I1RXFP1TP53LMNAP2RX7 | |
| SCHEMBL30948120 | 0.77 | IL4I1 (0.74) | IL4I1KCNH2P2RX7NPY5R | |
| SCHEMBL30948361 | 0.76 | IL4I1 (0.66) | IL4I1RXFP1TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240246937-A1 | IL4I1 INHIBITORS AND METHODS OF USE | MERCK SHARP & DOHME LLC (US) | 2024-07-25 | — | — | US | disclosed |
| EP-4329889-A1 | IL4I1 INHIBITORS AND METHODS OF USE | Merck Sharp & Dohme LLC (US) | 2024-03-06 | — | — | EP | disclosed |
| WO-2022232333-A1 | IL4I1 INHIBITORS AND METHODS OF USE | MERCK SHARP & DOHME LLC (US) | 2022-11-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240246937-A1 | IL4I1 INHIBITORS AND METHODS OF USE | IL4I1, IL4, IL2 | IL4I1 1/4885RXFP1 1354/4885TP53 1444/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.